Neurocognitive Disorders Clinical Trial
Official title:
Construction and Empirical Study of Personalized Intervention Based on Health Portrait in Mild Behavioral Impairment
The incidence of MBI and the probability of progression to dementia are high. Early detection and intervention have important clinical significance to reduce the occurrence of dementia, delay the progression of dementia and promote healthy aging to active aging. The occurrence and development of NPS in MBI patients may be related to genetic and degenerative changes in the central nervous system. The evaluation of MBI patients is mainly based on neuropsychological tests, including NPS and cognitive function assessment. Landmark model is an effective tool for dynamic risk prediction of the progress of MBI. It can make dynamic prediction at different time points according to various existing measurement indicators of an individual and calculate the individual prediction probability, which is one of the best models for studying the outcome of disease at present. The Landmark model is applied to the elderly MBI population to study the influencing factors of normal aging, MBI and dementia and the probability of metastasis, which is a beneficial attempt to further advance the defense line of dementia. Personalized non-drug intervention is the preferred treatment for MBI, which mainly includes cognitive/emotional intervention, sensory stimulation, exercise therapy, etc. Currently, it is recommended to adopt diversified strategies to implement individualized precision treatment programs for patients. The hierarchical and classified health management of elderly MBI patients combined with health portrait technology is helpful to improve management efficiency and better meet the needs of personalized health management for the elderly.
Status | Not yet recruiting |
Enrollment | 60 |
Est. completion date | December 30, 2027 |
Est. primary completion date | December 30, 2026 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 60 Years and older |
Eligibility | Inclusion Criteria: - Meet the ISTAART diagnostic criteria for MBI; - Age =60 years old; - No obvious visual or hearing impairment; - Have the ability of language communication, can complete the scale assessment. Exclusion Criteria: - Patients with severe physical diseases and unable to complete cognitive function screening; - Patients with other neurological diseases and serious medical diseases that can cause brain dysfunction. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Fujian Provincial Hospital |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | General cognitive function | The Montreal Cognitive Assessment Scale, developed by Nasreddine in 2004 to assess participants' general cognitive function, covers eight areas of cognitive assessment, including visuospatial and executive function, naming, memory, attention, speech, abstraction, delayed recall, and orientation. The Changsha version of the Montreal Cognitive Assessment Scale was used in this study, and its Cronbach's a coefficient was 0.846, retest reliability was 0.974, and investigator reliability was 0.969. The score of the Montreal Cognitive Assessment Scale ranges from 0 to 30 points. The higher the score, the better the cognitive function of the study subjects. The illiterate group =13, the primary school group =19, and the junior high school and above group =24 can be judged as impaired cognitive function to correct the bias caused by education level | The intervention was conducted in September 2024, and the evaluation time was 0,3 months separately | |
Secondary | Sleep condition | The Pittsburgh Sleep Quality Index, developed by Buysse equals in 1989, was used to evaluate the sleep status of the participants over the past month. The Pittsburgh Sleep Quality Index includes seven components: subjective sleep quality, sleep duration, sleep duration, sleep efficiency, sleep disorders, hypnotic drugs, and daytime function, with good internal consistency (Cronbach's a=0.83) and retest reliability (r=0.85). The cumulative score for each component of the Pittsburgh Sleep Quality Index Scale is the total score of the scale, ranging from 0 to 21, with a score of 0 to 3 for each component, with higher scores associated with poorer sleep quality | The intervention was conducted in September 2024, and the evaluation time was 0,3 months separately | |
Secondary | Social participation | The Social Support Rating Scale was used to assess participants' social participation. This study adopted the social support assessment compiled by domestic scholar Xiao Shuiyuan, which has good reliability and validity (Cronbach's a coefficient is 0.83). There are 10 items in the social support evaluation, including objective support, subjective support and social support utilization. The score ranges from 11 to 40 points. The higher the score of each dimension, the higher the degree of social support. It is generally believed that the total score of 20 is poor social support, 20-30 is general social support, and 30-40 is satisfactory social support | The intervention was conducted in September 2024, and the evaluation time was 0,3 months separately | |
Secondary | Dementia conversion rate | The Condensed Mental State Scale, developed by Folstein et al., is increasingly being used to screen patients for dementia, determine the severity of cognitive impairment, and determine dementia transition. The sensitivity and specificity of the concise mental State scale in the screening diagnosis of dementia are 80-90% and 70-80%. The scale covers cognitive areas such as orientation, memory, attention and computation, speech and visuospatial. The Condensed Mental State Scale ranges from 0 to 30 points. Dementia can be graded according to the Condensed Mental State Scale, with mild dementia scoring 21-26, moderate dementia 11-20, and severe dementia 0-10 | The intervention was conducted in September 2024, and the evaluation time was 0,3 months separately | |
Secondary | Psychological symptoms | The Neuropsychiatric Scale (NPI) is also a suitable tool for assessing NPS in patients with MBI. The Neuropsychiatric Scale is a scale developed by Cummings et al. to assess NPS in dementia patients, including hallucinations, delusions, agitation/aggression, anxiety, depression, euphoria, loss, disinhibition, abnormal movement, appetite disorders, sleep and nocturnal behavior disorders. The Chinese version of neuropsychiatric scale has good reliability and validity with Cronbach's a coefficient of 0.851, bias coefficient of 0.83, and total retest reliability of 0.86. The neuropsychiatric scale is easy to use and provides a way for semi-structured interviews to distinguish symptoms of inhibition from symptoms of apathy. Neuropsychiatric scale patient scores ranged from 0-144, caregiver pain scores ranged from 0-60, the lower the score the better | The intervention was conducted in September 2024, and the evaluation time was 0,3 months separately | |
Secondary | Behaviour impairment | The Mild Behavioral Impairment checklist (MBI-Checklist) asseses subjects to assess the symptoms and severity of MBI and was developed by ISTAART after the publication of diagnostic criteria for MBI in 2016. The mild behavioral impairment Checklist, filled out by a family member or someone in the know, has five categories, including lack of motivation, emotional incoordination, impulse control disorders, social withdrawal, and perceptual or thinking abnormalities. The sensitivity and specificity of the mild behavioral impairment checklist were 86.96% and 86.00%. The mild behavioral Impairment Checklist scores range from 0 to 102, with the higher the total score, the higher the degree of mild behavioral impairment | The intervention was conducted in September 2024, and the evaluation time was 0,3 months separately |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05754567 -
CONCEPTT Kids International Neurodevelopmental Outcomes Among Offspring of Women With Type 1 Diabetes
|
||
Completed |
NCT05080777 -
Pilot Pragmatic Clinical Trial to Embed Tele-Savvy Into Health Care Systems
|
N/A | |
Not yet recruiting |
NCT03276377 -
VItamin K Inhibition and NeurocoGnition (VIKING)
|
N/A | |
Completed |
NCT04175223 -
Impact of Probiotics in HIV-positive Patients With Neurocognitive Disorders
|
N/A | |
Completed |
NCT03538522 -
A Double-Blind, Placebo-Controlled Safety and Efficacy Study of NA-831
|
Phase 2 | |
Recruiting |
NCT05732285 -
A Pilot Randomized Controlled Trial: CoINTEGRATE
|
N/A | |
Recruiting |
NCT04095962 -
Effects of a Multicomponent Exercise Intervention on Physical and Cognitive Function of Older Adults With Dementia
|
N/A | |
Not yet recruiting |
NCT04113577 -
COgilus Remediation in Alzheimer Patients (CORA)
|
||
Recruiting |
NCT06320639 -
DRIVing Simulator and People With NeuroCognitive Disorders
|
||
Recruiting |
NCT06105320 -
COGNIFOOD-Changing the Carbohydrate/Fat-ratio to Prevent Cognitive Decline and Alzheimer Pathology: A Pilot Study
|
N/A | |
Completed |
NCT03050385 -
Cognitive Rehabilitation During Transcranial Direct Current Stimulation
|
N/A | |
Active, not recruiting |
NCT06372002 -
Effectiveness and Cost-Effectiveness of Cognitive Stimulation Therapy - Spain (CST-ES) in People Living With Dementia
|
N/A | |
Recruiting |
NCT05508789 -
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)
|
Phase 3 | |
Recruiting |
NCT03926351 -
High Dose Omega 3 in People at Risk for Dementia
|
Phase 2 | |
Recruiting |
NCT05504681 -
Integration of Neurocognitive Biomarkers Into a Neuro-Oncology Clinic
|
||
Completed |
NCT04168268 -
Patient-reported Outcome Measures After Post-anesthesia Care Unit Delirium
|
||
Recruiting |
NCT04825847 -
Neurocognitive Disorders After Major Surgery in Elderly
|
N/A | |
Active, not recruiting |
NCT02958670 -
Imaging Tau Deposition in the Brain of Elderly Subjects
|
N/A | |
Enrolling by invitation |
NCT02652598 -
Evaluate the Effects of Tolcapone on Cognitive and Behavioral Dysfunction in Patients With BI and NCD
|
Phase 2 | |
Completed |
NCT02825732 -
MEMORA-Caregiver : Risk Factors of Caregiver Burden Among Patients With Neurocognitive Disorders or Subjective Cognitive Complaint
|
N/A |